Precigen Shares Rise on Positive Long-Term Follow-Up Data From Papzimeos

Dow Jones

2025/10/13

By Chris Wack

Precigen shares were up 6%, to $3.32, in premarket trading after the company said it saw positive long-term follow-up data for Papzimeos for treatment of adults with recurrent respiratory papillomatosis.

Papzimeos was granted full approval by the Food and Drug Administration in August.

The biopharmaceutical company said Papzimeos approval was supported by results from a study that met its primary safety and pre-specified primary efficacy endpoints. Papzimeos was well tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2.

The Germantown, Md., company said 51%, or 18 out of 35, of study patients achieved complete response, requiring no surgeries in the 12-month period after treatment with Papzimeos.

Precigen said prolonged reduction in the requirement for surgical intervention to manage RRP was observed throughout long-term follow-up of evaluable study patients compared to the year prior to treatment.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

October 13, 2025 07:54 ET (11:54 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2575334405"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575334405\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575334405?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 19:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575334405","market":"fut","top_or_hot":-1,"title":"Precigen Shares Rise on Positive Long-Term Follow-Up Data From Papzimeos","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/PGEN\">Precigen</a> shares were up 6%, to $3.32, in premarket trading after the company said it saw positive long-term follow-up data for Papzimeos for treatment of adults with recurrent respiratory papillomatosis. \n</p>\n<p>\n  Papzimeos was granted full approval by the Food and Drug Administration in August. \n</p>\n<p>\n  The biopharmaceutical company said Papzimeos approval was supported by results from a study that met its primary safety and pre-specified primary efficacy endpoints. Papzimeos was well tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2. \n</p>\n<p>\n  The Germantown, Md., company said 51%, or 18 out of 35, of study patients achieved complete response, requiring no surgeries in the 12-month period after treatment with Papzimeos. \n</p>\n<p>\n  Precigen said prolonged reduction in the requirement for surgical intervention to manage RRP was observed throughout long-term follow-up of evaluable study patients compared to the year prior to treatment. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 13, 2025 07:54 ET (11:54 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Precigen Shares Rise on Positive Long-Term Follow-Up Data From Papzimeos</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrecigen Shares Rise on Positive Long-Term Follow-Up Data From Papzimeos\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-10-13 19:54</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/PGEN\">Precigen</a> shares were up 6%, to $3.32, in premarket trading after the company said it saw positive long-term follow-up data for Papzimeos for treatment of adults with recurrent respiratory papillomatosis. \n</p>\n<p>\n  Papzimeos was granted full approval by the Food and Drug Administration in August. \n</p>\n<p>\n  The biopharmaceutical company said Papzimeos approval was supported by results from a study that met its primary safety and pre-specified primary efficacy endpoints. Papzimeos was well tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2. \n</p>\n<p>\n  The Germantown, Md., company said 51%, or 18 out of 35, of study patients achieved complete response, requiring no surgeries in the 12-month period after treatment with Papzimeos. \n</p>\n<p>\n  Precigen said prolonged reduction in the requirement for surgical intervention to manage RRP was observed throughout long-term follow-up of evaluable study patients compared to the year prior to treatment. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 13, 2025 07:54 ET (11:54 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PGEN","symbol_name":"Precigen","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2575334405","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575334405","pubTimestamp":1760356440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Precigen shares were up 6%, to $3.32, in premarket trading after the company said it saw positive long-term follow-up data for Papzimeos for treatment of adults with recurrent respiratory papillomatosis.Papzimeos was granted full approval by the Food and Drug Administration in August.The biopharmaceutical company said Papzimeos approval was supported by results from a study that met its primary safety and pre-specified primary efficacy endpoints. Papzimeos was well tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2.The Germantown, Md., company said 51%, or 18 out of 35, of study patients achieved complete response, requiring no surgeries in the 12-month period after treatment with Papzimeos.Precigen said prolonged reduction in the requirement for surgical intervention to manage RRP was observed throughout long-term follow-up of evaluable study patients compared to the year prior to treatment.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PGEN":"Precigen","BK4139":"生物科技"},"translate_title":"Precigen股价因Papzimeos积极的长期随访数据而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGEN":1.5},"content_text":"By Chris Wack \n\n\n \n\n\nPrecigen shares were up 6%, to $3.32, in premarket trading after the company said it saw positive long-term follow-up data for Papzimeos for treatment of adults with recurrent respiratory papillomatosis. \n\n\n  Papzimeos was granted full approval by the Food and Drug Administration in August. \n\n\n  The biopharmaceutical company said Papzimeos approval was supported by results from a study that met its primary safety and pre-specified primary efficacy endpoints. Papzimeos was well tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2. \n\n\n  The Germantown, Md., company said 51%, or 18 out of 35, of study patients achieved complete response, requiring no surgeries in the 12-month period after treatment with Papzimeos. \n\n\n  Precigen said prolonged reduction in the requirement for surgical intervention to manage RRP was observed throughout long-term follow-up of evaluable study patients compared to the year prior to treatment. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 13, 2025 07:54 ET (11:54 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}